Form 4: Cidara Therapeutics COO & CLO, Shane Ward, Reports Acquisition of Shares and Stock Options

Shane Ward, COO & CLO of Cidara Therapeutics, reports the acquisition of 25,000 shares of common stock and 50,000 employee stock options on March 31, 2025.

Summary

• On March 31, 2025, Shane Ward, the COO & CLO of Cidara Therapeutics, acquired 25,000 shares of common stock.
• These shares were granted as time-based Restricted Stock Units (RSUs) at a price of $0.
• The RSUs vest in three equal annual installments starting March 10, 2026, and continuing in 2027 and 2028, contingent upon continuous service.
• Ward also acquired 50,000 employee stock options with an exercise price of $21.54.
• These options vest in 36 successive equal monthly installments from the vesting commencement date of March 31, 2025.
• Following these transactions, Ward directly owns 39,674 shares of common stock and 50,000 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The acquisition of shares and options by an executive is generally a good sign, but it's a routine transaction.

Positives

• The acquisition of shares and stock options by a key executive like the COO & CLO can be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The vesting schedules for the RSUs and stock options indicate a long-term commitment from the executive to the company's success.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. These filings are closely watched by investors for insights into management's perspective on the company's value and future prospects.

Comparison to Industry Standards

• Stock option grants and RSU awards are common forms of executive compensation in the biotechnology industry, used to align management's interests with those of shareholders.
• The vesting schedules described are fairly standard, with both time-based and performance-based vesting being common.
• The specific terms of the grants (number of shares, exercise price, vesting schedule) would need to be compared to those of peer companies to determine if they are above or below industry averages.

Stakeholder Impact

• The reported transactions could have a minor positive impact on shareholder sentiment, as they reflect the executive's confidence in the company.

Key Dates

Keywords

Cidara Therapeutics, Shane Ward, stock options, RSUs, Form 4, beneficial ownership, insider trading